Regeneron PharmaceuticalsNASDAQ: REGN

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Regeneron investments or would like to inquire about potentially pursuing claims to recover your loss under the fede.

Regeneron's stock dropped by 9.2% following the Q3 2024 report, which made the company's valuation look more appealing. This report was the 15th out of 16 in the past four years that exceeded expectations. Investors were concerned about the slowing sales growth of EYLEA and the uncertain revenue forecasts for 2024.

Regeneron's stock is dropping sharply due to recent legal issues with Eylea and Amgen introducing a lower-dose biosimilar version of the drug. However, investors might be exaggerating the negative effects of this situation. Meanwhile, Dupixent continues to grow rapidly with increasing profit margins from collaborations, and Libtayo is also showing strong revenue growth.

Regeneron has announced third-quarter results that exceeded expectations, surpassing both earnings and revenue forecasts. This success is mainly due to strong sales of Eylea HD, Dupixent, and Libtayo.

Regeneron (REGN) reported quarterly earnings of $12.46 per share, which is higher than the Zacks Consensus Estimate of $11.75 per share. This is an increase compared to earnings of $11.59 per share from the same period last year.

TARRYTOWN, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has released its financial results for the third quarter of 2024 and shared an update on its business activities.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will hold its Q3 2024 Earnings Conference Call on October 31, 2024, at 8:30 AM ET. Key company participants include Ryan Crowe, Leonard Schleifer, George Yancopoulos, Marion McCourt, and Chris Fenimore. Various analysts from firms like JPMorgan, TD Cowen, and Goldman Sachs will also join the call.

When REGN shares its third-quarter 2024 results, investors will probably pay close attention to how well Dupixent is doing and how popular Eylea HD has become.

Here are some biotech stocks to watch in the current stock market. It's important to stay updated on these companies. They may present interesting investment opportunities.